Annual Reports

Quarterly Reports


  • 8-K (Feb 8, 2018)
  • 8-K (Feb 6, 2018)
  • 8-K (Dec 14, 2017)
  • 8-K (Dec 5, 2017)
  • 8-K (Jun 26, 2017)
  • 8-K (May 31, 2017)


Osiris Therapeutics 8-K 2008

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Graphic
  4. Graphic








Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): December 31, 2007



(Exact Name of Registrant as Specified in Charter)







(State or other jurisdiction of


(Commission File Number)


(IRS Employer





Identification No.)






7015 Albert Einstein Drive, Columbia, Maryland



(Address of principal executive offices)


(Zip Code)


Registrant’s telephone number, including area code: (443) 545 - 1800


Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b))


o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




ITEM 1.01 Entry Into Material Definitive Agreement.


On January 7, 2008, Osiris Therapeutics, Inc. (the “Company,” “Osiris”or “Registrant”) issued a press release announcing the termination of its long-term collaboration agreement with Boston Scientific Corporation (“BSC”) and that it had regained the worldwide rights to cardiovascular indications for Prochymal.  The original agreements were entered into in 2003 and focused upon the development and commercialization of the Registrants technology to treat cardiovascular disease throughout the world.  BSC paid the Registrant a $5 million licensing fee which was being recognized over a 63-month time period,  BSC purchased 500,000 shares of the Registrant’s common stock in 2003 for $10 million and, provided Osiris with a $50 million line of credit.  In 2004, the Company drew $5 million under the line.


Under the terms of the termination agreement, Osiris immediately regained worldwide rights to its stem cell technology for all cardiovascular indications.  The parties agreed to cancel the $50 million line of credit and Osiris agreed to repay the $5 million outstanding balance, plus accrued interest over four quarterly installments.


ITEM 7.01 Regulation FD Disclosure.


On January 7, 2008, the Company issued a press release announcing that it had terminated its long-term collaboration agreement with Boston Scientific Corporation and regained the worldwide rights to cardiovascular indications for its stem cell technology, as further described in Item 1.01 of this Form 8-K.


The text of Item 1.01 of this Form 8-K is incorporated into this Item 7.01 by reference..


The press release announcing the termination agreement is attached as Exhibit 99.1 to this Current Report on Form 8-K.


The information included in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing (including any Item of this filing) pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in this or such filing, incorporating by reference such information.


ITEM 9.01. Financial Statements and Exhibits.


(d)        Exhibits .


99.1                           Press Release of the Registrant dated January 7, 2008.






Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.







Dated: January 7, 2008






Philip R. Jacoby, Jr.



Interim Chief Financial Officer






Exhibit No.








Press Release of the Registrant dated January 7, 2008



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki